January 8: 2023 Advocacy year in review 2023 December 11: Take Action to Prevent Damaging Reimbursement Cuts! November 20: AAN Members Provide Perspective at AMA Meeting November 6: How Will the CMS Fee Schedule Affect You? October 23: Reps Hear Proposal to Cut 'Red Tape' October 9: Partic...
TG Therapeutics will present BRIUMVI® data on multiple sclerosis at the AAN 2025 annual meeting in San Diego. Quiver AI Summary TG Therapeutics, Inc. has announced its schedule for presenting data on BRIUMVI® (ublituximab-xiiy) at the upcoming American Academy of Neurology ...
In a significant win for AAN advocacy, theCenters for Medicare and Medicaid Services (CMS) is rescinding theAppropriate Use Criteria (AUC) programand all implementing regulations to allow for reevaluation. As outlined in the 2024 Medicare Physician Fee Schedule (PFS) final rule, CMS states that...
“The new analyses from the Phase 3 MycarinG and Phase 3 RAISE XT open-label extension (OLE) studies being presented at this year’s AAN meeting reinforce the potential of our recently approved gMG treatments, RYSTIGGO®...